Population pharmacokinetics of recombinant factor VIII:C (ReFacto®) in adult HIV-negative and HIV-positive haemophilia patients

[1]  Anika Ashok,et al.  Guidance for Industry by U.S. Department of Health and Human Services—Food and Drug Administration—Center for Biologics Evaluation and Research (CBER)—February 1999 , 2009 .

[2]  Kathleen A. Johnson,et al.  Medical Costs and Resource Utilization for Hemophilia Patients With and Without HIV or HCV Infection , 2007, Journal of managed care pharmacy : JMCP.

[3]  R. Boulieu,et al.  A Limited Sampling Strategy for Estimating Individual Pharmacokinetic Parameters of Coagulation Factor VIII in Patients With Hemophilia A , 2007, Therapeutic drug monitoring.

[4]  State of the art international symposium on pharmacokinetics of factor concentrates in haemophilia: challenges and relevance to clinical practice. Summary statement , 2006 .

[5]  M. Morfini,et al.  The pharmacokinetics of coagulation factors , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  M. Tapper,et al.  Emerging viral diseases and infectious disease risks , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  J. Korth-Bradley,et al.  Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  D. W. Hawkins,et al.  Population pharmacokinetics of racemic warfarin in adult patients , 1985, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  J. Ahnström,et al.  A 6‐year follow‐up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  M. Morfini,et al.  Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain‐deleted recombinant factor VIII , 2004, British journal of haematology.

[11]  L. Iacoviello,et al.  HIV infection, HAART, and endothelial adhesion molecules: current perspectives. , 2004, The Lancet. Infectious diseases.

[12]  J. Wilde,et al.  HIV and HCV coinfection in haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  J. Lusher,et al.  The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  M. Morfini.  Pharmacokinetics of factor VIII and factor IX , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  S. Björkman.  Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  M. Mikaelsson,et al.  Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. , 2001, Seminars in hematology.

[17]  E. Berntorp,et al.  Pharmacokinetics of Coagulation Factors , 2001, Clinical pharmacokinetics.

[18]  N. Binkin,et al.  Epidemiology of hemophilia and of HIV infection in Italy. GICC. Gruppo Italiano Coagulopatie Congenite. , 1994, Journal of clinical epidemiology.